Case of the month from ONCO Pathology:Glioblastoma Multiforme
🔬📚 In this month's edition of our monthly case series, we're diving into an intriguing case of Glioblastoma Multiforme.
Clinical History:A 46 year old male presented with right side body weakness of 1 month duration associated with progressive headache of similar duration.
Investigation:
CT scan
a well circumscribed, hemorrhagic lesion in the left cerebellum with minimal perilesional oedema and mild enhancement with contrast.
MRI
The mass was hyperintense on T1-weighted, hypointense on T2-wieghted with minimal adjacent edema and mild enhancement with gadolinium contrast.
Biopsy
hypercellular proliferation of markedly pleomorphic astrocytic cells with pseudopalisading necrosis accompanied prominent microvascular proliferation. Mitosis is conspicuous
Case Diagnosis: Glioblastoma multiforme, WHO grade IV
Case Discussion:Glioblastoma multiforme (GBM) is an aggressive brain cancer originating from astrocytes, classified as a grade IV glioma with rapid growth.
It is the most common primary brain tumor in adults, accounting for 15% of cases, with an incidence of 3-4 per 100,000, more common in males.
The exact cause of GBM is unclear, but genetic mutations (e.g., EGFR, TP53) and environmental factors may contribute.
Increased risk factors for GBM include age, male gender, family history of brain tumors, prior head radiation, and certain genetic syndromes.
Common symptoms include persistent headaches, nausea, cognitive changes, seizures, neurological deficits, vision and speech problems, and fatigue.
Diagnosis involves neurological exams, imaging studies (MRI, CT scan), and biopsy for histological examination.
GBM treatment typically includes surgery, radiation therapy, chemotherapy (Temozolomide), targeted therapy, and emerging immunotherapies.
Prognosis is generally poor, with a median survival of about 15 months, influenced by patient age, performance status, tumor resection extent, and genetic markers.
GBM is a grade IV tumor marked by high cellularity, pleomorphic cells, necrosis, and vascular proliferation, indicating aggressive malignancy.
🖌📖 Don't miss out on the opportunity to explore this fascinating case study and expand your knowledge in the field.🔓
https://docs.google.com/document/d/1M-wRd51Yk63l6DDFRNG-s4AXu76AJYizYxBrht5VmIA/edit?usp=sharing
@HakimEthio
🔬📚 In this month's edition of our monthly case series, we're diving into an intriguing case of Glioblastoma Multiforme.
Clinical History:A 46 year old male presented with right side body weakness of 1 month duration associated with progressive headache of similar duration.
Investigation:
CT scan
a well circumscribed, hemorrhagic lesion in the left cerebellum with minimal perilesional oedema and mild enhancement with contrast.
MRI
The mass was hyperintense on T1-weighted, hypointense on T2-wieghted with minimal adjacent edema and mild enhancement with gadolinium contrast.
Biopsy
hypercellular proliferation of markedly pleomorphic astrocytic cells with pseudopalisading necrosis accompanied prominent microvascular proliferation. Mitosis is conspicuous
Case Diagnosis: Glioblastoma multiforme, WHO grade IV
Case Discussion:Glioblastoma multiforme (GBM) is an aggressive brain cancer originating from astrocytes, classified as a grade IV glioma with rapid growth.
It is the most common primary brain tumor in adults, accounting for 15% of cases, with an incidence of 3-4 per 100,000, more common in males.
The exact cause of GBM is unclear, but genetic mutations (e.g., EGFR, TP53) and environmental factors may contribute.
Increased risk factors for GBM include age, male gender, family history of brain tumors, prior head radiation, and certain genetic syndromes.
Common symptoms include persistent headaches, nausea, cognitive changes, seizures, neurological deficits, vision and speech problems, and fatigue.
Diagnosis involves neurological exams, imaging studies (MRI, CT scan), and biopsy for histological examination.
GBM treatment typically includes surgery, radiation therapy, chemotherapy (Temozolomide), targeted therapy, and emerging immunotherapies.
Prognosis is generally poor, with a median survival of about 15 months, influenced by patient age, performance status, tumor resection extent, and genetic markers.
GBM is a grade IV tumor marked by high cellularity, pleomorphic cells, necrosis, and vascular proliferation, indicating aggressive malignancy.
🖌📖 Don't miss out on the opportunity to explore this fascinating case study and expand your knowledge in the field.🔓
https://docs.google.com/document/d/1M-wRd51Yk63l6DDFRNG-s4AXu76AJYizYxBrht5VmIA/edit?usp=sharing
@HakimEthio
tgoop.com/HakimEthio/32758
Create:
Last Update:
Last Update:
Case of the month from ONCO Pathology:Glioblastoma Multiforme
🔬📚 In this month's edition of our monthly case series, we're diving into an intriguing case of Glioblastoma Multiforme.
Clinical History:A 46 year old male presented with right side body weakness of 1 month duration associated with progressive headache of similar duration.
Investigation:
CT scan
a well circumscribed, hemorrhagic lesion in the left cerebellum with minimal perilesional oedema and mild enhancement with contrast.
MRI
The mass was hyperintense on T1-weighted, hypointense on T2-wieghted with minimal adjacent edema and mild enhancement with gadolinium contrast.
Biopsy
hypercellular proliferation of markedly pleomorphic astrocytic cells with pseudopalisading necrosis accompanied prominent microvascular proliferation. Mitosis is conspicuous
Case Diagnosis: Glioblastoma multiforme, WHO grade IV
Case Discussion:Glioblastoma multiforme (GBM) is an aggressive brain cancer originating from astrocytes, classified as a grade IV glioma with rapid growth.
It is the most common primary brain tumor in adults, accounting for 15% of cases, with an incidence of 3-4 per 100,000, more common in males.
The exact cause of GBM is unclear, but genetic mutations (e.g., EGFR, TP53) and environmental factors may contribute.
Increased risk factors for GBM include age, male gender, family history of brain tumors, prior head radiation, and certain genetic syndromes.
Common symptoms include persistent headaches, nausea, cognitive changes, seizures, neurological deficits, vision and speech problems, and fatigue.
Diagnosis involves neurological exams, imaging studies (MRI, CT scan), and biopsy for histological examination.
GBM treatment typically includes surgery, radiation therapy, chemotherapy (Temozolomide), targeted therapy, and emerging immunotherapies.
Prognosis is generally poor, with a median survival of about 15 months, influenced by patient age, performance status, tumor resection extent, and genetic markers.
GBM is a grade IV tumor marked by high cellularity, pleomorphic cells, necrosis, and vascular proliferation, indicating aggressive malignancy.
🖌📖 Don't miss out on the opportunity to explore this fascinating case study and expand your knowledge in the field.🔓
https://docs.google.com/document/d/1M-wRd51Yk63l6DDFRNG-s4AXu76AJYizYxBrht5VmIA/edit?usp=sharing
@HakimEthio
🔬📚 In this month's edition of our monthly case series, we're diving into an intriguing case of Glioblastoma Multiforme.
Clinical History:A 46 year old male presented with right side body weakness of 1 month duration associated with progressive headache of similar duration.
Investigation:
CT scan
a well circumscribed, hemorrhagic lesion in the left cerebellum with minimal perilesional oedema and mild enhancement with contrast.
MRI
The mass was hyperintense on T1-weighted, hypointense on T2-wieghted with minimal adjacent edema and mild enhancement with gadolinium contrast.
Biopsy
hypercellular proliferation of markedly pleomorphic astrocytic cells with pseudopalisading necrosis accompanied prominent microvascular proliferation. Mitosis is conspicuous
Case Diagnosis: Glioblastoma multiforme, WHO grade IV
Case Discussion:Glioblastoma multiforme (GBM) is an aggressive brain cancer originating from astrocytes, classified as a grade IV glioma with rapid growth.
It is the most common primary brain tumor in adults, accounting for 15% of cases, with an incidence of 3-4 per 100,000, more common in males.
The exact cause of GBM is unclear, but genetic mutations (e.g., EGFR, TP53) and environmental factors may contribute.
Increased risk factors for GBM include age, male gender, family history of brain tumors, prior head radiation, and certain genetic syndromes.
Common symptoms include persistent headaches, nausea, cognitive changes, seizures, neurological deficits, vision and speech problems, and fatigue.
Diagnosis involves neurological exams, imaging studies (MRI, CT scan), and biopsy for histological examination.
GBM treatment typically includes surgery, radiation therapy, chemotherapy (Temozolomide), targeted therapy, and emerging immunotherapies.
Prognosis is generally poor, with a median survival of about 15 months, influenced by patient age, performance status, tumor resection extent, and genetic markers.
GBM is a grade IV tumor marked by high cellularity, pleomorphic cells, necrosis, and vascular proliferation, indicating aggressive malignancy.
🖌📖 Don't miss out on the opportunity to explore this fascinating case study and expand your knowledge in the field.🔓
https://docs.google.com/document/d/1M-wRd51Yk63l6DDFRNG-s4AXu76AJYizYxBrht5VmIA/edit?usp=sharing
@HakimEthio
BY Hakim
Share with your friend now:
tgoop.com/HakimEthio/32758